Cavli Wireless Starts Manufacturing of LPWAN, LTE, and 5G IoT Modules in India Based on GCT Semiconductor Chipsets
Cavli Wireless, has partnered with GCT Semiconductor and licensed the chipsets, to manufacture and produce LPWAN, LTE, and 5G IoT modules in India. This will be the first-ever initiative to kickstart the manufacturing of industry-grade LTE/LPWAN IoT modules in India. India is an emerging hub of IoT product development for the global market and an IoT module designed, developed, and manufactured in India is already welcoming news for Cavli’s existing customer base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005181/en/
C42GM is a single-mode LTE CAT M1/NB1/NB2 (upgradable to Release 14) compatible Smart Cellular Module based on 3GPP Release 13, that comes with an integrated eSIM. C42GM has a healthy battery life profile of ten years due to Deep Sleep Mode capability. It also comes with integrated GNSS, Bluetooth 4.2 & Sigfox. The integrated eSIM coupled with Cavli Hubble Global Connectivity ensures the module can be deployed across the globe, making it an ideal solution for logistics, automotive, vehicle tracking systems and more (Photo: Business Wire)
GCT Semiconductor, Inc. designs and develops innovative LTE chipset solutions for the 4G LTE, LPWAN, and 5G wireless communication industry.
A key highlight in this collaboration, LTE CAT M1/NB1/NB2 C42GM Smart IoT Module based on GCT GDM7243i, comes with an integrated eSIM, GNSS, CAN controller, and BLE-4.2, making it every asset tracking and automotive solution makers’ dream hardware. Furthermore, the C42GM smart IoT module is Sigfox compatible as well making it an attractive option for organizations focusing on hybrid connectivity solutions. A wide variety of LPWAN applications/use cases like trackers, wearables, smart utility meters, and other sensor-based solutions for smart city projects can be seamlessly powered with the eSIM integrated C42GM smart IoT module with global connectivity.
The ever-growing wireless connectivity industry now refueled by the added push for digitization efforts, in the wake of the pandemic, is setting the stage for India to emerge as a global electronic manufacturing hub for the developed markets. This partnership with GCT Semiconductor is positioning Cavli Wireless as a preferred global partner for many enterprise IoT projects where the market is demanding connectivity hardware products with a high level of integration.
Currently running pilots with customers around the globe, the first IoT module from this partnership - C42GM will start shipping out globally, on a mass production basis from Q1 2021.
IoT solution makers interested in pre-ordering an Evaluation Kit can visit the link for the same.
About Cavli Wireless, Inc.
Cavli Wireless is a cellular IoT module manufacturer, headquartered in San Jose, California, that combines IoT connectivity and data management into one single platform. Cavli designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite development processes for a variety of applications, including smart city deployments, industrial automation, logistics and transportation, healthcare, and human safety. All smart modules developed by Cavli are equipped with global cellular connectivity through integrated eSIM functionality that provides users with affordable global data pricing, simplified device management processes, and centralized subscription management through their proprietary cloud-based interface Cavli Hubble.
About GCT Semiconductor, Inc.
GCT Semiconductor is a leading fabless designer and supplier of advanced 4G LTE and 5G semiconductor solutions. GCT’s market-proven LTE solutions have enabled fast and reliable LTE connectivity to numerous commercial devices such as smartphones, tablets, hotspots, USB dongles, routers, M2M applications, etc., for the world’s top LTE carriers. GCT offers LTE solutions optimized for the Internet of Things (IoT). GCT’s system-on-chips integrate radio frequency, baseband modem and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability and cost effectiveness. For more information, visit www.gctsemi.com.
Co-founder & CMO, Cavli Wireless
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Colicity Inc. Announces Closing of $345 Million Initial Public Offering26.2.2021 23:00:00 CET | Press release
Colicity Inc. (the “Company”) announced the closing today of its initial public offering of 34,500,000 units, including the underwriters’ exercise of their full over-allotment option for 4,500,000 units, at a price of $10.00 per unit. The units are listed on the NASDAQ Stock Market (NASDAQ) and began trading under the ticker symbol “COLIU” on February 24, 2021. Each unit consists of one Class A share and one-fifth of one redeemable warrant, with each whole warrant exercisable to purchase one Class A share at a price of $11.50 per share. Only whole warrants will be exercisable. Once the securities comprising the units begin separate trading, the Class A shares and warrants are expected to be listed on the NASDAQ under the symbols “COLI” and “COLIW,” respectively. Colicity Inc. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company int
C3 AI and Baker Hughes to Provide Enterprise AI Solutions to Accelerate PETRONAS Digital Transformation Program26.2.2021 15:00:00 CET | Press release
C3 AI (NYSE: AI) and Baker Hughes today announced an artificial intelligence (AI) collaboration with PETRONAS, a global energy and solutions company from Malaysia, to apply BakerHughesC3.ai (BHC3) technology across PETRONAS’s strategic digital transformation programs. As the custodian of Malaysia's national oil and gas resources, PETRONAS runs an extensive digital transformation program across energy operations to extract value from data. The adoption of AI as part of its overall program for improved oil and gas productivity, asset integrity, and safety supports PETRONAS’s commitment to provide clean, efficient energy solutions by harnessing the power of technology. PETRONAS will work with energy technology, data science, and AI experts at Baker Hughes and C3 AI to collaborate on projects focused on improved reliability of energy assets in critical operations. Utilizing Microsoft Azure, PETRONAS will deploy the BHC3™ Reliability application to further improve maintenance programs for g
Avania in Position for Next Stage of Growth26.2.2021 14:00:00 CET | Press release
Avania, a leading global full-service contract research organization (CRO) focused on medical technology (MedTech) development, today announced that it has successfully refinanced its existing banking facilities with Crescent Capital Group. “This new banking facility allows us to accelerate our next phase of organic and acquisitive growth over the next few years,” said Edo van Houten, CFO of Avania. “This transaction is also a reflection of the progress we have made in our brand strategy and position in the market, and it demonstrates the confidence of the financial community in our operational and strategic plan.” Avania has navigated confidently through the COVID-19 pandemic, posting a strong year of growth in 2020 despite the pandemic. The company will continue its growth trajectory as a global MedTech-focused CRO, supporting products from concept through post-market support. MedTech is all Avania does, navigating innovative medical technologies to market effectively and efficiently
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx ® in Combination With Opdivo ® as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma26.2.2021 12:37:00 CET | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) for the first-line treatment of advanced renal cell carcinoma (aRCC). The European Commission, which has the authority to approve medicines for the European Union (E.U.), will now review the CHMP recommendation and a final decision on the application in the E.U. is expected in the coming months. “Advanced renal cell carcinoma is a disease that significantly impacts the lives of people around the world. We’re proud to be able to share that the CHMP has confirmed a positive recommendation for Cabometyx® in combination with Opdivo®, bringing this impactful new treatment option one step closer for patients,” said Howard Mayer, Executive Vice President and Head of Research and Development, Ipsen. “At Ipsen, w
Hiro Capital Leads $15 Million of Games VC Investment Into Snowprint Studios, Double Loop Games and Happy Volcano Games26.2.2021 09:55:00 CET | Press release
Three international video game studios are the latest investments for Hiro Capital, the entrepreneur-led Venture Capital fund focused on backing innovators in Video Games, the Metaverse, Esports and Digital Fitness. The three mobile and cross-platform studios – Snowprint in Stockholm/Berlin, Double Loop Games in San Francisco and Happy Volcano in Belgium – will use Hiro’s investment to expand their development pipelines and accelerate global growth. They join UK and US Games studios Flavourworks, Polyarc and Lightfox in the Hiro Capital portfolio, alongside pioneers in the gamification of Games Streaming and Digital Fitness LIV.tv, Edgegap,FitXR and Nurvv. Ian Livingstone, co-founding partner at Hiro Capital, said, "We are excited to begin 2021 by announcing Hiro's investment in three amazing games studios, Snowprint, Double Loop and Happy Volcano. Each studio has demonstrated innovation and expertise in developing fun to play games which resonate with today’s audiences. I’m especially
Inspur Information Releases 2020 Global Computing Index Report26.2.2021 09:07:00 CET | Press release
Inspur Information, a leading IT infrastructure solutions provider, has sponsored an International Data Corporation (IDC) white paper on the 2020 Global Computing Index (henceforth referred to as The Report). As the world’s first index report on computing, The Report unveils the relationship between computing power and economic development and serves as a reference for the outlook of the global digital economy. Global digital transformation has entered a phase marked by exponential growth in innovation, with the size of the digital economy projected to continue on an upward trend. As a key factor that underlies digital technology development, computing is now defining the productivity of the digital economy era. According to The Report, economic growth directly correlates with the development of computing—one point of growth in the computing index translates to a 3.3‰ rise in the size of the digital economy and a 1.8‰ growth in GDP. Specifically, AI computing market share is projected
Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)26.2.2021 09:00:00 CET | Press release
Incyte (Nasdaq:INCY) today announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group Vice President, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent U.S. Food & Drug Administration acceptance of our Biologics License Application for Priority Review – brings us
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom